Management of Post-transplantation Diabetes Mellitus(PTDM)

Chosun University Hospital Lee Hae Jeong

Total treatment performed in the Korean to data(2013)



KONOS data 2013

End stage renal disease with diabetes mellitus



J Korean Soc Transplant 2009;23:123-129

Post-transplant diabetes mellitus following liver transplantation





J Korean Med Sci 2009;24:567-570

Estimated rate of post-transplant diabetes mellitus

14-74%	Kidney transplants
7-30%	Liver transplants
11-38%	heart transplants
6-45%	lung transplants
15%	Bone marrow transplants

transplant

12 months

Transplantation 80:945, 2005. Transplantation 88:429, 2009. Liver transplantation 15. Suppl 2:S79, 2009. Transplantation 89:1526, 2010



Patient survival after kidney transplant: effect of diabetes



Important to decrease the incidence of PTDM

- Avoid complications of PTDM in each individual transplant recipient
- Protect the social investment already made in the transplant recipient
- Optimize the distribution of a scarce resource

Criteria of Post-transplant diabetes mellitus



New onset diabetes after transplant(NODAT)



 Not all diabetes is "new" so may prefer term Post –Transplant Diabetes(PTDM)

Clin J Am Soc Nephrol 2010;5:1669-1675

Criteria of Post-transplant diabetes mellitus

- Follows ADA criteria
- Doesn't distinguish time from transplant
 1 month and 10 years considered same
- A1C less reliable so not an established criteria
- NODAT is spontaneous remission
- 50% people; Improvement in glucose tolerance after the immunosuppressive agents decrease or taper

Mechanism in the pathogenesis of PTDM

Pre-transplant

Post-transplant



Incidence of PTDM among nondiabetes

Type of graft	Incidence estimate
Kidney	14-74%
Liver	7-30%
Heart	11-38%

Incidence varies with patient population and center immunosuppression used, diabetes screening protocol, interval of testing, who is looking at that data!

> Transplantation 80:945, 2005. Transplantation 88:429, 2009. Liver transplantation 15. Suppl 2:S79, 2009. Transplantation 89:1526, 2010

Post-Transplant Diabetes Risk Factors



Glucocorticoid steroids is



Clin j Am Soc Nephrol 2:343-355

Immunosuppresant can cause hyperglycemia

	Cyclosporine A	Tacrolimus	Sirolimus
Glucose intolerance	+ 6%	+ + + 8.4%	+ 6.6%
Hypertension	++	+	
Hyperlipidemia	++	_	+++

Calcineurin inhibitors and sirolimus Can cause hyperglycemia



Transplantation 82(4):466-70. 2006

Approach to management of PTDM

Similarities of type 2 DM and PTDM



J Clin Invest 1981;68:1456-1467

Management aim of PTDM



Prediction of hyperglycemia and risk of PTDM



Diabetes Care 34;2141-2145; 2011

Waiting transplant ...

- Document baseline blood glucose status
- Assess diabetes risk factors
- Identify high-risk subjects
- Initiate lifestyle intervention

 Dietary counseling
 Exercise counseling

Post-transplant period

- Immunosuppressive regimen

 Minimize steroid dose
 Minimize calcineurin inhibitor exposure
- Treat hyperglycemia beginning in the peritransplant period
- Close follow-up of all patients , especially those with prediabetes

Post-transplant period

- for those develop NODAT
 - diabetes education
 - appropriate medical therapy based of severity of hyperglycemia
- optimize insulin therapy during episodes of high-dose steroid exposure

Can lifestyle modification be adapted for prevention of PTDM?

Type 2DM PTDM

Obesity !

Nutr Clin Pract 2007;22:494-504

Prevalence of obesity at the time of transplantation among transplant recipients



Nutr Clin Pract 2007;22:494-504

For the lower the incidence of NODAT

Insulin resistance After transplantation

Obesity treatment

seems to reasonable target for intervention

Higher BMI before transplantation

Lifestyle intervention Studies for the Prevention of type 2 DM

Study	Population	Duration	Conclusions (intervention vs control)
Malmo Feasibility study	181 IGT vs 193 IGT or NGT	5 and12 y	37%↓
Da Qing study	577 IGT	6у	46% vs 67.7%
DPS	522 IGT	3.2 у	11% vs 23%
DPP study	3234 with IGT or IFG	2.8 y	58%↓
Malmohus study	267 men with IGT	10 y	13% vs 29%

Percent developing diabetes(DPP study) All participants





Effect of higher muscle on survival in HD patients



DM of renal failure
<u>coronary artery d's</u>
Cerebrovascular d's
peripheral Vascular d's
<u>heart failure</u>

High BMI(≥25Kg/m²) group by muscle mass

J Am Soc Nephrol 14:2366-2372. 2003



Potential effectiveness of lifestyle intervention importance



J Nephrol Nurs 2011;38:139-147; quiz 148





AACE system of intensive diabetes self-management -2000

Treatment guideline for Post-transplantation diabetes mellitus



ADA, JNC proposal of recommendation 2011

Self monitoring blood glucose

Maximization of curative effect

HbA1c <7.0%

OHA Therapy Insulin therapy Lifestyle modification interval: 3months
Especially attention
: Renal failure
: anemia

J korean Soc Transplant 2011;25:8-14

Glucose control: should goals be different?

ADA guidelines		
CU	140-180mg/dl	
Non- ICU	Pre-meal < 140mg/dl Random < 180mg/dl	

Diabetes care 36 Suppl 1;S11-66, 2013

Value of tighter control?

Kidney Transplant RCT: 70-100 vs <180mg/dl

More hypoglycemia, rejections => no benefit

JCEM 97; 4399, 2012

Insulin therapy

Several stressors after trans-plants surgery



Thus

Treatment goals Resting the β-cell with Basal insulin and β-cell Protection with near-normo-glycemic control :reduce IGT and NODAT

Clin J Am Soc Nephrol 2010;5:1669-1675

Insulin therapy

Used widely

Basal insulin, split-mix, basal-bolus

Flexibility and creativity

Oral agents post-transplant

Oral /SQ agent	Effective Post-TX?	Potential limitations
Sulfonylureas & repaglinide	Yes	Drug-durg interactions with cyclosporine, risk of hypoglycemia with GFR \downarrow , less with repaglinide
Metformin	Yes	Contraindicated in hospital with GFR \downarrow , LFTs \uparrow , CHF, infection
Exenatide	Not studied	
DPP-IV inhibitors	Yes	Reduce dose for most with GFR \downarrow
TZDs	Yes	Risk of LFTs \uparrow , CHF, weight gain
Acarbose	Yes	Avoid with GFR \downarrow , ineffective as single agent

Hypoglycemia can

- Induce seizure and arrhythmia
- Triggers adrenergic discharge
- Expression of pro-inflammatory cytokines



Adverse outcomes in high-risk patients

Dyslipidemia

- Calcineurin inhibitors: increase cholesterol level
 Preferentially pravastatin, fluvastatin
- Sirolimus and glucocorticoids: increase hypertriglyceridemia
 Be used fibrate, fish oil

Hypertension

- Premorbid hypertension
- Recommends BP: 130/80 mmHg \downarrow
- ß-blockers, calcium channel blockers to be effective
- ACE inhibitors, ARB are associated decreases in GFR and hyperkalemia

Clin J Am Soc Nephrol 2010;5:703-708

Transition to home: always tricky

- Diet
- Exercise
- Sick day management
- Self-blood glucose monitoring
- Insulin injection method



You are what you eat!

Fib rich meal Food is insipid Standard body weight

Regular diet

Attention to monosaccharides

Attention to Fatty food

What about foods high in carbohydrates?

- Come from sugars and starches
- provide fuel and energy
- Take steroid medication, it's difficult for your body to use extra carbohydrates



What about cholesterol and triglyceride levels?



Still need to follow a low-salt diet?

- Transplant medications, Steroids may cause to retain fluid
- Salt makes this problem worse, increasing fluid retention and raising blood pressure

ww.kidney.org





What about protein?

- Especially...
- It builds and repairs muscles and tissues
- It helps you heal after surgery
- 1.0g~1.2g/Kg (15~20%/ day)







Take care of the meal

- Calcium-rich foods
- Food rich dietary fiber _



-suitable



Not eat the health supplements food



Will gain weight?

- Many people have a better appetite after they get a transplant, and gain unwanted weight.
- Avoid high-calorie foods, fatty foods, sweets, pastries, sugar
- Important to controlling weight
 Help to: exercise and regular physical activity plan



American of transplantation 2009;9:S64-S70



Thank you for your attention